Impact of Baseline “Ellipsoid Zone At-Risk” Burden on Geographic Atrophy Natural History Growth Rate in the ReCLAIM-2 Clinical Trial

摘要: Purpose: To evaluate automated baseline assessment of ellipsoid zone (EZ) At-Risk burden and assess the impact of this biomarker on the natural history geographic atrophy (GA) growth in the ReCLAIM-2 clinical trial.Methods: ReCLAIM-2 is a Phase 2 prospective, randomized clinical trial of elamipretide, a mitochondrial protective agent, compared to placebo in advanced dry age-related macular degeneration (AMD) with GA at week 48. All baseline scans that were of sufficient quality for analysis and segmentation from patients in the placebo arm that completed the week 48 visit were included.